Compound reference

Tirzepatide Dosage Guide 2026: Label, Trials, Compounded

By the Decadewise team Education only Last updated 9 August 2026 13 cited sources

Short answer

Two incretin receptors, one molecule: tirzepatide is a once-weekly injectable that activates GIP and GLP-1 together.

SURMOUNT-1 tested three doses: the phase 3 obesity trial (Jastreboff, NEJM 2022) ran them once weekly over 72 weeks:

5mg
10mg
15mg

What the top arm did: 15mg lost about 20.9% of body weight at 72 weeks, against 3.1% on placebo.

A prescription counts milligrams, a barrel counts units: the two only agree once the concentration is known, and the approved labels print eleven different ones.

What a wrong concentration does to an ordinary dose: it can make it look twenty times bigger on paper, the arithmetic under the panic posts we have read.

Approved under two brand names: Mounjaro for type 2 diabetes, Zepbound for weight management. Neither a research vial nor a compounded vial is that product: a compounder sets its own concentration, with no approved label, so no Mounjaro or Zepbound figure transfers. Every trial figure comes straight from the cited papers, DOIs at the bottom.

Convert a dose in milligrams into syringe units

The four numbers it needs: vial strength, diluent volume, barrel scale, and the milligram figure being converted. It returns the concentration, the volume, and the reading on the barrel.

Reference page, or the bare tool: this one is the compound reference, and it owns the tirzepatide dosage question: what the label specifies, what the trials assigned, what compounded actually means, and what the arithmetic does with all three. For the tool alone, the tirzepatide dosage calculator runs the same conversion with the approved label concentrations laid out beside it.

Units converter

Converts the numbers you type. It does not recommend a dose.

Vial amount mg Bacteriostatic water mL Syringe type Barrel size Dose you want to convert mg

Concentration5 mg per mL

Volume to drawenter a dose

Reads as

Arithmetic only. This is arithmetic on the numbers entered. It has no knowledge of any real vial, reconstitution, or syringe.

On this page

Short answer Convert a dose to units How the units math works Does 2.5mg have one units number? Compounded vs the label product Reported use What did the trials do? Trial dose vs internet dose What's not known yet? The safety picture How this page is sourced The disclaimer

How does the units math work?

One pass through the arithmetic, with nobody in it: the figures below belong to a vial and a water volume.

A 10mg research vial in 2mL: reconstituted with that much bacteriostatic water, it holds 5mg per mL, which is 5,000mcg per mL.

What one unit buys at that concentration: on a U-100 barrel 100 units make a milliliter, so a single unit is 0.01mL and carries 50mcg, 0.05mg, here. 2.5mg lands on 50 units, and 5mg fills the barrel.

The same vial in half the water: 10mg in 1mL rather than 2mL doubles the concentration, to 10mg per mL.

Which halves every reading: a unit carries 0.1mg where it carried 0.05mg, so the same 2.5mg reads 25 units, not 50.

So a posted "50 units" describes a plunger position, not an amount: at the first concentration those fifty units hold 2.5mg and at the second they hold 5mg, and the post carries no way to say which.

Same 10mg vial, two reconstitutions, on a U-100 syringe

Water added	Concentration	1 unit equals	What the article works out
2mL	5mg per mL (5,000mcg per mL)	0.05mg (50mcg)	2.5mg is 50 units, 5mg is 100 units
1mL	10mg per mL	0.1mg	2.5mg is 25 units, not 50

Arithmetic on the vial and water amounts in the first column, nothing else. No label and no trial specifies any of these figures.

Syringe scale, before any concentration math

Syringe	Units per mL	1 unit equals
U-100	100 units per mL	0.01mL
U-40	40 units per mL	0.025mL

Definitional: the number in a syringe's name is its units per mL. The fixed 0.5mL Mounjaro dose reads as 50 units on the first row and 20 on the second.

The brand side: a Mounjaro single-dose pen or single-dose vial delivers its dose in a fixed 0.5mL, straight from the label. That fixed 0.5mL reads as 50 units on a U-100 syringe; the multi-dose vial and the KwikPen deliver 0.6mL per dose, 60 units. The units question only exists for vials you mix yourself.

Which is a good place to notice what that 50 units is resting on: the 0.5mL is a label figure and the 50 is not, because the same 0.5mL is 20 units on a U-40 barrel. The scale table beside this one is the reason the conversion needs a second input the label never supplies, and the barrel prints its number identically either way.

Does 2.5mg of tirzepatide have one units number?

No, and further down this page it is run across eleven concentrations: at 5mg per mL, a 10mg vial plus 2mL of water, 2.5mg reads as 50 units on a U-100 syringe. The same vial in 1mL sits at 10mg per mL instead, where it reads 25 units. Same milligrams, same syringe, half the mark.

The eleven-row version further down is the same two rows continued: nothing changes between them except the water, and the reading moves every time it does. Our dose math index keeps that variable separate from the milligram figure for exactly this reason, since collapsing the two is what produces a chart that looks authoritative and applies to one vial.

Compounded tirzepatide dosage: what the label specifies, and what a compounded vial inherits from it

Start here, because the rest of this page does not apply otherwise: compounded tirzepatide is not the approved product. It is made by a different party, to a formulation and a concentration that party chooses, and it has no approved label of its own. Every figure elsewhere on this page comes from the Mounjaro and Zepbound labels or from the trials that supported them, and none of it describes what is in a compounded vial.

What compounding is, in the statute rather than in marketing: compounded drugs are exempt from certain requirements under sections 503A and 503B of the Federal Food, Drug and Cosmetic Act. FDA states the position plainly: compounded drugs are not FDA approved, and the agency does not review them for safety, effectiveness or quality before they are marketed. A 503A pharmacy compounds for an individual patient on receipt of a prescription. A 503B outsourcing facility may compound from a bulk drug substance only if that substance is on the 503B bulks list, or if the drug is on FDA's shortage list at the time of compounding, distribution and dispensing.

Where tirzepatide sits in that framework right now: as of FDA's compounder update current to 1 April 2026, tirzepatide and semaglutide appear on neither the 503B bulks list nor FDA's drug shortage list. The route that let outsourcing facilities make near-identical copies at scale ran through the shortage listing, and that listing is gone. The chronology below is FDA's own, including the litigation, because this is a live dispute and a page that reports only one side of it is not reporting.

Compounded tirzepatide: the regulatory record, by date

Date	What the record says	Source
15 December 2022	Tirzepatide injection products added to FDA's drug shortage list	FDA declaratory order, 19 December 2024
2 October 2024	FDA determines the shortage resolved and removes the products from the list	FDA declaratory order; FDA compounder update
7 October 2024	FDA sued in the Northern District of Texas by the Outsourcing Facilities Association and North American Custom Laboratories over the removal, No. 4:24-cv-953	FDA declaratory order, footnote 2
11 October 2024	On FDA's own motion, the court remands the decision to the agency for reevaluation	FDA declaratory order, footnote 2
19 December 2024	FDA issues a declaratory order revoking and replacing the October decision, again determining the shortage resolved	FDA declaratory order
18 February 2025	Stated end of the 503A enforcement-discretion window, set at 60 days from the December announcement, then clarified to run to that date or the court's preliminary-injunction decision, whichever is longer	FDA compounder update, 11 February 2025
5 March 2025	District court denies the plaintiffs' preliminary injunction motion, and FDA states the 503A period of enforcement discretion has ended	FDA compounder update, 10 March 2025
19 March 2025	Stated end of the 503B window for outsourcing facilities, set at 90 days, on the same whichever-is-longer condition	FDA compounder update
1 April 2026	FDA states tirzepatide and semaglutide are on neither the 503B bulks list nor the drug shortage list	FDA compounder update, content current as of 1 April 2026

Every row is a date and an action recorded in an FDA document, references 7 and 8. We report no outcome the agency has not published, and the case docket is given so the record can be followed past this page.

Now the part that matters for arithmetic: the approved product's concentration is not one number, and a compounded vial's concentration is not on this list at all unless its own label happens to match. Here is what the approved labels print.

Tirzepatide concentration chart, from the approved labels only

Presentation	Doses per container	Volume per injection	Strength per mL	Source
Single-dose pen or single-dose vial	1	0.5mL	5, 10, 15, 20, 25 or 30mg per mL, one per dose strength	Mounjaro PI section 3; Zepbound PI section 3
Multi-dose vial	4	0.6mL, printed on the label	4.17, 8.33, 12.5, 16.7, 20.8 or 25mg per mL, printed on the label	Mounjaro PI section 3; Zepbound PI section 3
Single-patient-use KwikPen	4	0.6mL, from 2.4mL over 4 doses	4.17, 8.33, 12.5, 16.7, 20.8 or 25mg per mL, printed on the label	Mounjaro PI section 3; Zepbound PI section 3

Strengths and per-mL figures are the label's own. The KwikPen's per-injection volume is the only derived number here: its label prints milligrams per injection and 2.4mL total across 4 doses, and 2.4 divided by 4 is 0.6.

Count the distinct concentrations in that table: the single-dose column carries six, the four-dose presentations carry six, and 25mg per mL appears in both, which leaves 11 different concentrations inside the approved product alone. That is before anyone compounds anything. A figure copied from one row is wrong on every other row, and the milligram number on the prescription never tells you which row you are on.

Why a compounded vial breaks the copy worse: FDA's own dosing-error alert describes the mechanism for the sibling compound. Compounded products come in various containers including multiple-dose vials, product concentrations vary depending on the compounder, and a single compounder may offer several concentrations of the same drug. The accompanying instructions may be written in units, whose volume depends entirely on the concentration, rather than in milligrams or milliliters.

What that produced, as reported adverse events rather than as a warning: in the reports FDA summarized for compounded semaglutide, patients drawing from multiple-dose vials administered five to 20 times more than the intended dose. One provider intended a 0.25mg dose, equal to 5 units at the concentration in question, and prescribed 25 units. Another prescribed 20 units instead of 2, affecting three patients. That alert is semaglutide-specific and we are not restating it as a tirzepatide finding; what carries across is the mechanism, which is a milligram figure meeting an unknown concentration.

The FDA counts, as of 31 May 2026: more than 730 adverse event reports associated with compounded tirzepatide, and 990 associated with compounded semaglutide. FDA notes state-licensed pharmacies that are not outsourcing facilities are not required by federal law to report, so it expects underreporting, and that many of the reported events look like the ones seen with the approved products.

distinct concentrations inside the approved product alone

compounded tirzepatide vials carrying an FDA-approved label

730+

FDA adverse event reports for compounded tirzepatide, as of 31 May 2026

5 to 20x

more than the intended dose, in measuring errors FDA documented with compounded semaglutide vials

Mounjaro and Zepbound prescribing information, section 3; FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, current as of 15 June 2026; FDA dosing-error alert, 26 July 2024.

So here is the arithmetic, which is the one thing that does transfer: the conversion does not care whose vial it is. It cares about two numbers, and both of them have to come off the container in front of you rather than off any page, this one included.

The two numbers: the concentration in milligrams per milliliter, and the syringe scale. Volume in milliliters equals the milligram amount divided by the concentration. Units equal that volume multiplied by 100 on a U-100 syringe, or by 40 on a U-40.

Worked across every approved concentration, so the spread is visible rather than asserted: the table below runs one fixed milligram figure, 2.5mg, through all 11. Nothing in it is a dose or a suggestion. It is one division and one multiplication, repeated.

What 2.5mg reads as at each concentration the approved labels print

Concentration	Where that concentration appears	2.5mg is	Reads as, U-100	Reads as, U-40
4.17mg per mL	multi-dose vial, 2.5mg dose	0.600mL	60 units	24 units
5mg per mL	single-dose 2.5mg per 0.5mL	0.500mL	50 units	20 units
8.33mg per mL	multi-dose vial, 5mg dose	0.300mL	30 units	12 units
10mg per mL	single-dose 5mg per 0.5mL	0.250mL	25 units	10 units
12.5mg per mL	multi-dose vial, 7.5mg dose	0.200mL	20 units	8 units
15mg per mL	single-dose 7.5mg per 0.5mL	0.167mL	16.7 units	6.7 units
16.7mg per mL	multi-dose vial, 10mg dose	0.150mL	15 units	6 units
20mg per mL	single-dose 10mg per 0.5mL	0.125mL	12.5 units	5 units
20.8mg per mL	multi-dose vial, 12.5mg dose	0.120mL	12 units	4.8 units
25mg per mL	single-dose 12.5mg per 0.5mL, and multi-dose 15mg dose	0.100mL	10 units	4 units
30mg per mL	single-dose 15mg per 0.5mL	0.083mL	8.3 units	3.3 units

Column 1 is from the labels (references 6 and 11). Columns 3 to 5 are arithmetic on column 1: 2.5 divided by the concentration, then multiplied by 100 or by 40. The multi-dose figures divide by the exact label ratios, 10 over 2.4 and so on, which is why 4.17 lands on 0.600mL rather than 0.5995mL.

Read the U-100 column end to end: the same 2.5mg spans 8.3 units to 60 units, a factor of more than seven, without leaving the approved product. Take in the U-40 column too and the spread runs 3.3 to 60 units, a factor of more than eighteen. Nothing in that range is more or less correct than anything else in it. The concentration decides, and only the concentration.

Which is the whole point about a compounded vial: its concentration is whatever its own label states, and if that number is not on the table above then no row on the table applies to it. Reading a unit count off a Mounjaro or Zepbound figure and drawing it from a compounded vial is not a small approximation. It is the arithmetic in the FDA reports above.

And what we will not do: name a number for a compounded vial. There is no approved label to quote, no trial that used that formulation, and no reading of the evidence that turns a figure for one product into a figure for another. What this section can hand over is the label's own numbers, the regulatory record with its dates, and a conversion that works on whatever is printed on the vial in front of you. The dose itself belongs to a doctor who can see your history.

Community reports, not a protocol

What do users report running?

The reported start: the schedule in the posts tracks the label: 2.5mg once weekly for the first four weeks, then 2.5mg steps.

The hold pattern: plenty of posters describe staying at 2.5mg or 5mg long past the four-week mark while weight keeps moving, instead of stepping up on schedule.

The splitting talk: threads discuss splitting the weekly dose into two smaller injections. No controlled trial has studied that pattern.

The units confusion: the loudest cluster is research-vial math. The same "50 units" gets quoted as 2.5mg by one poster and 5mg by the next, because the vials and water amounts differ.

The churn: posters describe cycling between brand pens, compounded vials, and research suppliers as cost and availability shift around them.

The regulator's count: the FDA has logged more than 730 adverse event reports tied to compounded tirzepatide as of 31 May 2026, and 990 for compounded semaglutide (FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, reference 9). A count of voluntary reports has no denominator, so it measures reporting as much as it measures harm.

Neither the label nor the trial: everything above is what users post. It is not what the trials ran, and it is not what the label specifies.

Peer-reviewed trial data

What did the trials do?

SURMOUNT-1, four arms: the pivotal obesity trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2539 adults without diabetes across four arms, weekly tirzepatide or placebo, for 72 weeks. The arms in the table below.

Twenty weeks of ramp before the target: the trial built in a dose-escalation period that long. The current label schedule starts at 2.5mg once weekly for the first four weeks, moves to 5mg, then steps up by 2.5mg when more effect is needed, to a 15mg maximum.

What the steps are protecting against: gastrointestinal side effects were the most common adverse events in the trial, and they occurred primarily during dose escalation.

Arm	Weekly dose	Escalation
placebo	0mg	none
low	5mg	2.5mg steps every 4 weeks
mid	10mg	2.5mg steps every 4 weeks
top	15mg	2.5mg steps every 4 weeks

Four arms, weekly tirzepatide or placebo, 72 weeks. SURMOUNT-1, Jastreboff et al., NEJM 2022.

The 72-week readout: the 15mg arm brought mean body weight down 20.9%, against 3.1% on placebo. The 10mg arm was down 19.5% and the 5mg arm 15.0%.

The deeper cut: 57% of the 15mg arm lost at least a fifth of their body weight, against 3% on placebo.

Read those as means: they are mean percentage changes, taken straight from the trial abstract.

The mechanism: it has its own paper, Coskun et al., Molecular Metabolism, 2018, the discovery and first-in-human work. Tirzepatide, LY3298176 in the papers, is a dual agonist at two receptors: GIP and GLP-1. Its glucagon-receptor activity is minimal, per the discovery paper.

The head-to-head: the SURPASS-2 trial (Frias et al., New England Journal of Medicine, 2021) ran 1879 people with type 2 diabetes for 40 weeks against semaglutide 1mg. HbA1c fell 2.01 to 2.30 percentage points across the three doses, against 1.86 on semaglutide, and tirzepatide was noninferior and superior at all three doses.

And the weight: down up to 5.5kg more than semaglutide at the 15mg dose. The paper reports the gap dose by dose as least-squares mean treatment differences of -1.9kg at 5mg, -3.6kg at 10mg and -5.5kg at 15mg, so the separation widens with the dose rather than holding flat across the three arms.

The monotherapy trial: SURPASS-1 (Rosenstock et al., The Lancet, 2021) put 478 people with type 2 diabetes controlled only by diet and exercise on tirzepatide or placebo for 40 weeks. HbA1c dropped 2.07 percentage points at 15mg while placebo barely moved, and bodyweight fell 7.0 to 9.5kg depending on dose.

The diabetes obesity trial: SURMOUNT-2 (Garvey et al., The Lancet, 2023) ran 938 people with overweight or obesity and type 2 diabetes for 72 weeks: down 12.8% at 10mg and 14.7% at 15mg, against 3.2% on placebo.

Those trials do not stack: different populations, different timepoints, different comparators.

20.9%

mean body weight down at 72 weeks, 15mg arm

19.5%

down at 72 weeks, 10mg arm

3.1%

on placebo at 72 weeks

2539

adults across four arms, none with diabetes

SURMOUNT-1 obesity trial, Jastreboff et al., NEJM 2022.

Is the trial dose the same as what people post?

What makes this comparison unusual among the compounds on this site: both columns below are full. Tirzepatide has a dose-ranging trial and an approved label, so the question is not whether a schedule exists but which of three schedules a given number came from.

What the trial's schedule is for

Why there are three arms and not one: the trials exist to answer research questions: does the drug beat placebo, does it beat semaglutide, and how much does the dose matter. That is why a 5mg arm sits next to a 10mg and a 15mg arm, on purpose, with a placebo arm too.

Dose-ranging evidence, and nothing beyond it: not a recommendation.

What people run online

Where the reported titrations drift: away from the label schedule in both directions, slower holds at 2.5mg or 5mg, or faster steps when a vial is running out. The trials and the label test one schedule; the forums test everything else.

What the pricing does to a schedule: a research vial costs the same drawn slow or drawn fast, which pushes toward stretching it. Brand pens price by the month, which pushes the other way.

A trial schedule, a label schedule and a forum schedule are three different objects that happen to be written in the same milligrams.

What is genuinely open here: not what the trials found, which is published and specific, but which product is in the vial and at what concentration. That is the one question the whole comparison above depends on, and it is answered by a supplier rather than by a study.

What's not known yet?

Approved twice, with a third indication added since: tirzepatide holds both. Mounjaro for type 2 diabetes since 2022, Zepbound for chronic weight management since 2023, with an obstructive sleep apnea indication added in 2024. Those dates come from the Drugs@FDA approval records rather than from the labels, and the distinction matters: both labels print an initial US approval of 2022, because that is when the molecule was first approved, not when either brand indication was.

The approval is not the caveat, the vial is: everything in the trials, the label schedule and the boxed warning describes the approved product, and a research-grade vial is not it.

What no trial has covered:

No controlled-trial data on the community patterns: dose splitting, long holds below the label steps, research-vial titration. None of it has been studied.
On stopping and restarting, SURMOUNT-MAINTAIN reports something. After a 60-week open-label lead-in at the maximum tolerated dose, which the trial defined as 10mg or 15mg once weekly, 378 participants were randomly assigned to continue that dose, to reduce to 5mg, or to switch to placebo for 52 more weeks, and from week 84 any of them became eligible for rescue tirzepatide if regain passed half the weight lost. Rescue was then given to 60 of 90 in the placebo group, 35 of 142 on 5mg and 11 of 138 on the maximum tolerated dose. Corrected 29 July 2026, when this line read that no verified data existed, and made specific about the arms and the rescue condition on 30 July 2026.
No published head-to-head between brand pen and research vial. The trials ran the same molecule the brands sell, nothing else.

No published trial reaches the first or the third, so nothing can be cited for them. The second now has one behind it, cited above.

And one that sits above the dose question entirely: the eleven concentrations in the table above are printed on approved labels. A research or compounded vial carries a twelfth number that no approved label prints and that FDA has not reviewed.

Identity, purity, sterility, strength: four claims a vial makes, and an approval is what puts a regulator behind them. FDA states that unapproved versions of GLP-1 drugs, naming semaglutide and tirzepatide, do not undergo its review for safety, effectiveness and quality before they are marketed, and says the same of compounded drugs. What testing any particular vial has been through, by whom, and for which of the four, is a question about that vial and its seller, and nothing on this page settles it.

The failure with no symptom: a mislabeled concentration breaks every units calculation above without showing itself, because the math is only ever as honest as the mg figure on the label. FDA reports fraudulent compounded semaglutide and tirzepatide marketed in the United States carrying false information on the product label, in some cases naming a compounding pharmacy that does not exist.

Which is why sourcing comes before dosing on this page: the concentration has to be real before any of the eleven rows above mean anything, and that is what would keep us up first.

How this page is sourced

Nothing here came from a summary site: every trial figure above was read off the abstract of the cited paper itself.

Thirteen sources, seven of them documents rather than papers: six papers, two prescribing information documents, and five FDA documents covering the compounding record and the approval dates, with DOIs, PubMed IDs and document dates below. Each is listed below with its identifier, and every figure on this page traces back to one of them.

The standard all thirteen had to meet: the full sourcing and citation-verification standard for this site lives on the methodology page. Corrections to any number on this page land there first.

Last reviewed: 19 July 2026.

1
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID 35658024.
2
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID 34170647.
3
Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6. PMID 34186022.
4
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X. PMID 37385275.
5
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009. PMID 30473097.
6
Eli Lilly and Company. Mounjaro (tirzepatide) injection, prescribing information, sections 2 and 3. Revised April 2026. DailyMed, U.S. National Library of Medicine. NDA 215866, current label.
7
U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound). Issued to Eli Lilly and Company, 19 December 2024. Cites sections 506C and 506E of the FD&C Act and the litigation docket Outsourcing Facilities Ass'n v. FDA, No. 4:24-cv-953 (N.D. Tex.). fda.gov, declaratory order.
8
U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug alerts and statements, content current as of 1 April 2026, with dated updates from 2 October 2024 onward. fda.gov, compounder policy update.
9
U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug alerts and statements, content current as of 15 June 2026. Source of the adverse event counts as of 31 May 2026. fda.gov, unapproved GLP-1 concerns.
10
U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Human drug compounding, content current as of 26 July 2024. Semaglutide-specific; cited here for the dosing-error mechanism only. fda.gov, compounded dosing-error alert.
11
Eli Lilly and Company. Zepbound (tirzepatide) injection, prescribing information, section 3. Revised April 2026. DailyMed, U.S. National Library of Medicine. NDA 217806, current label.
12
Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407(10545):2305-2318. doi:10.1016/S0140-6736(26)00656-2. PMID 42119587. Registered as NCT06047548. An erratum was published in the same issue, Lancet 2026;407(10545):2290, doi:10.1016/S0140-6736(26)01134-7. Authors, subtitle and pagination added 30 July 2026 from the PubMed esummary, HTTP 200 that day; the entry previously carried a bare title and journal.
13
US Food and Drug Administration. Drugs@FDA approval records for tirzepatide, read for approval dates rather than label content. Mounjaro, NDA 215866, original application approved 13 May 2022; Zepbound, NDA 217806, original application approved 8 November 2023. The obstructive sleep apnea indication arrived with Zepbound supplement S-013, approved 20 December 2024, whose approval letter states that it "provides for the addition of a new indication for Zepbound: to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity". Approval letter, NDA 217806 S-013. Approval dates retrieved 31 July 2026 from the openFDA drugsfda API and the letter PDF, both HTTP 200.

The disclaimer

Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice.

It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.